{
    "root": "7bae176f-58e3-4d75-9609-80079f391e1e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Carvedilol Phosphate",
    "value": "20250506",
    "ingredients": [
        {
            "name": "CARVEDILOL PHOSPHATE",
            "code": "EQT531S367",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3441"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C GREEN NO. 3",
            "code": "3P3ONR6O1S"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "HYDROGENATED COTTONSEED OIL",
            "code": "Z82Y2C65EA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14334"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        }
    ],
    "indications": {
        "text": "carvedilol phosphate extended-release capsules alpha-/beta-adrenergic blocking agent indicated treatment : mild severe chronic heart failure . ( 1.1 ) left ventricular dysfunction following myocardial infarction clinically stable patients . ( 1.2 ) hypertension . ( 1.3 )",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carvedilol phosphate extended-release capsules intended once-daily . patients controlled immediate-release carvedilol tablets alone combination medications may switched carvedilol phosphate extended-release capsules based total daily doses shown table 1. table 1. dosing conversion daily dose immediate-release carvedilol tablets daily dose carvedilol phosphate extended-release capsulesa 6.25 mg ( 3.125 mg twice daily ) 10 mg daily 12.5 mg ( 6.25 mg twice daily ) 20 mg daily 25 mg ( 12.5 mg twice daily ) 40 mg daily 50 mg ( 25 mg twice daily ) 80 mg daily switching carvedilol 12.5 mg 25 mg twice daily , starting dose carvedilol phosphate extended-release capsules 20 mg 40 mg daily , respectively , may warranted elderly patients increased risk hypotension , dizziness , syncope . subsequent titration higher doses , appropriate , made interval least 2 weeks . carvedilol phosphate extended-release capsules taken daily morning food . carvedilol phosphate extended-release capsules swallowed whole . carvedilol phosphate extended-release capsules and/or contents crushed , chewed , taken divided doses . alternative capsules may carefully opened beads sprinkled spoonful applesauce . applesauce warm could affect modified-release properties formulation . mixture applesauce consumed immediately entirety . applesauce mixture stored future . absorption beads sprinkled foods tested .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "hard gelatin extended-release capsules available following strengths : 10 mg \u2013 capsules white opaque body imprinted \u201c h31 \u201d black ink dark green opaque cap . bottles 30 : ndc 69238-2577-3bottles 90 : ndc 69238-2577-9bottles 100 : ndc 69238-2577-1bottles 1,000 : ndc 69238-2577-2 20 mg \u2013 capsules white opaque body imprinted \u201c h32 \u201d black ink bright orange opaque cap . bottles 30 : ndc 69238-2578-3bottles 90 : ndc 69238-2578-9bottles 100 : ndc 69238-2578-1bottles 1,000 : ndc 69238-2578-2 40 mg \u2013 capsules bright orange opaque body imprinted \u201c h33 \u201d black ink dark green opaque cap . bottles 30 : ndc 69238-2579-3bottles 90 : ndc 69238-2579-9bottles 100 : ndc 69238-2579-1bottles 1,000 : ndc 69238-2579-2 80 mg \u2013 capsules white opaque body imprinted \u201c h34 \u201d black ink white opaque cap . bottles 30 : ndc 69238-2580-3bottles 90 : ndc 69238-2580-9bottles 100 : ndc 69238-2580-1bottles 1,000 : ndc 69238-2580-2 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tightly closed , light-resistant container defined usp , child-resistant closure , required . keep reach children .",
    "adverseReactions": "carvedilol phosphate extended-release capsules contraindicated following conditions : bronchial asthma related bronchospastic conditions . deaths status asthmaticus reported following single doses immediate-release carvedilol . second- third-degree av block . sick sinus syndrome . severe bradycardia ( unless permanent pacemaker place ) . patients cardiogenic shock decompensated heart failure requiring intravenous inotropic therapy . patients first weaned intravenous therapy initiating carvedilol phosphate extended-release capsules . patients severe hepatic impairment . patients history serious hypersensitivity reaction ( e.g . , stevens-johnson syndrome , anaphylactic reaction , angioedema ) carvedilol components carvedilol phosphate extended-release capsules .",
    "indications_original": "Carvedilol phosphate extended-release capsules are an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure. ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients. ( 1.2 ) hypertension. ( 1.3 )",
    "contraindications_original": "Carvedilol phosphate extended-release capsules are intended for once-daily administration. Patients controlled with immediate-release carvedilol tablets alone or in combination with other medications may be switched to carvedilol phosphate extended-release capsules based on the total daily doses shown in Table 1.\n                  \n                     Table 1. Dosing Conversion\n                  \n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Daily Dose of Immediate-Release\n                              \n                              \n                                 Carvedilol Tablets\n                              \n                           \n                           \n                              \n                                 Daily Dose of Carvedilol Phosphate\n                              \n                              \n                                 Extended-Release Capsulesa\n                                 \n                              \n                           \n                        \n                        \n                           \n                              6.25 mg (3.125 mg twice daily)\n                           \n                           \n                              10 mg once daily\n                           \n                        \n                        \n                           \n                              12.5 mg (6.25 mg twice daily)\n                           \n                           \n                              20 mg once daily\n                           \n                        \n                        \n                           \n                              25 mg (12.5 mg twice daily)\n                           \n                           \n                              40 mg once daily\n                           \n                        \n                        \n                           \n                              50 mg (25 mg twice daily)\n                           \n                           \n                              80 mg once daily\n                           \n                        \n                        \n                           \n                              \n                                 a When switching from carvedilol 12.5 mg or 25 mg twice daily, a starting dose of carvedilol phosphate extended-release capsules 20 mg or 40 mg once daily, respectively, may be warranted for elderly patients or those at increased risk of hypotension, dizziness, or syncope. Subsequent titration to higher doses should, as appropriate, be made after an interval of at least 2 weeks.\n                           \n                        \n                     \n                  \n                  Carvedilol phosphate extended-release capsules should be taken once daily in the morning with food. Carvedilol phosphate extended-release capsules should be swallowed whole. Carvedilol phosphate extended-release capsules and/or their contents should not be crushed, chewed, or taken in divided doses.\n                  \n                     Alternative Administration\n                     \nThe capsules may be carefully opened and the beads sprinkled over a spoonful of applesauce. The applesauce should not be warm because it could affect the modified-release properties of this formulation. The mixture of drug and applesauce should be consumed immediately in its entirety. The drug and applesauce mixture should not be stored for future use. Absorption of the beads sprinkled on other foods has not been tested.",
    "warningsAndPrecautions_original": "The hard gelatin extended-release capsules are available in the following strengths:\n                  \n                     10 mg \u2013 capsules with white opaque body imprinted with \u201cH31\u201d in black ink and dark green opaque cap.\n                  Bottles of 30:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2577-3Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2577-9Bottles of 100:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2577-1Bottles of 1,000:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2577-2\n                  \n                     20 mg \u2013 capsules with white opaque body imprinted with \u201cH32\u201d in black ink and bright orange opaque cap.\n                  Bottles of 30:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2578-3Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2578-9Bottles of 100:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2578-1Bottles of 1,000:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2578-2\n                  \n                     40 mg \u2013 capsules with bright orange opaque body imprinted with \u201cH33\u201d in black ink and dark green opaque cap.\n                  Bottles of 30:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2579-3Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2579-9Bottles of 100:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2579-1Bottles of 1,000:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2579-2\n                  \n                     80 mg \u2013 capsules with white opaque body imprinted with \u201cH34\u201d in black ink and white opaque cap.\n                  Bottles of 30:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2580-3Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2580-9Bottles of 100:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2580-1Bottles of 1,000:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-2580-2\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. \n                  DISPENSE IN A TIGHTLY CLOSED, LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP, WITH A CHILD-RESISTANT CLOSURE, AS REQUIRED. \n                  KEEP OUT OF THE REACH OF CHILDREN.",
    "adverseReactions_original": "Carvedilol phosphate extended-release capsules are contraindicated in the following conditions:\n                  \n                     Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of immediate-release carvedilol.\n                     Second- or third-degree AV block.\n                     Sick sinus syndrome.\n                     Severe bradycardia (unless a permanent pacemaker is in place).\n                     Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol phosphate extended-release capsules.\n                     Patients with severe hepatic impairment.\n                     Patients with a history of a serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to carvedilol or any of the components of carvedilol phosphate extended-release capsules.",
    "drug": [
        {
            "name": "Carvedilol Phosphate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3441"
        }
    ]
}